262 related articles for article (PubMed ID: 25032991)
1. Molecular mechanism of thiazolidinedione-mediated inhibitory effects on osteoclastogenesis.
Zhao D; Shi Z; Warriner AH; Qiao P; Hong H; Wang Y; Feng X
PLoS One; 2014; 9(7):e102706. PubMed ID: 25032991
[TBL] [Abstract][Full Text] [Related]
2. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
Gong W; Dou H; Liu X; Sun L; Hou Y
Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
[TBL] [Abstract][Full Text] [Related]
3. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
[TBL] [Abstract][Full Text] [Related]
4. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
[TBL] [Abstract][Full Text] [Related]
5. Kalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss.
Li L; Yang M; Shrestha SK; Kim H; Gerwick WH; Soh Y
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669069
[TBL] [Abstract][Full Text] [Related]
6. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
[TBL] [Abstract][Full Text] [Related]
7. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
[TBL] [Abstract][Full Text] [Related]
8. The naturally derived small compound Osthole inhibits osteoclastogenesis to prevent ovariectomy-induced bone loss in mice.
Zhao D; Wang Q; Zhao Y; Zhang H; Sha N; Tang D; Liu S; Lu S; Shi Q; Zhang Y; Dong Y; Wang Y; Shu B
Menopause; 2018 Dec; 25(12):1459-1469. PubMed ID: 29944638
[TBL] [Abstract][Full Text] [Related]
9. Oleanolic acid exerts inhibitory effects on the late stage of osteoclastogenesis and prevents bone loss in osteoprotegerin knockout mice.
Zhao D; Shu B; Wang C; Zhao Y; Cheng W; Sha N; Li C; Wang Q; Lu S; Wang Y
J Cell Biochem; 2020 Jan; 121(1):152-164. PubMed ID: 31318102
[TBL] [Abstract][Full Text] [Related]
10. Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-κB/c-Fos/NFATc1 Pathways.
Wei ZF; Tong B; Xia YF; Lu Q; Chou GX; Wang ZT; Dai Y
PLoS One; 2013; 8(3):e59171. PubMed ID: 23536866
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis.
Jules J; Zhang P; Ashley JW; Wei S; Shi Z; Liu J; Michalek SM; Feng X
J Biol Chem; 2012 May; 287(19):15728-38. PubMed ID: 22416138
[TBL] [Abstract][Full Text] [Related]
12. Oleanolic acid exerts bone protective effects in ovariectomized mice by inhibiting osteoclastogenesis.
Zhao D; Li X; Zhao Y; Qiao P; Tang D; Chen Y; Xue C; Li C; Liu S; Wang J; Lu S; Shi Q; Zhang Y; Dong Y; Wang Y; Shu B; Feng X
J Pharmacol Sci; 2018 May; 137(1):76-85. PubMed ID: 29703642
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo.
Franco GC; Kajiya M; Nakanishi T; Ohta K; Rosalen PL; Groppo FC; Ernst CW; Boyesen JL; Bartlett JD; Stashenko P; Taubman MA; Kawai T
Exp Cell Res; 2011 Jun; 317(10):1454-64. PubMed ID: 21420951
[TBL] [Abstract][Full Text] [Related]
14. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
Nakagawa S; Omori K; Nakayama M; Mandai H; Yamamoto S; Kobayashi H; Sako H; Sakaida K; Yoshimura H; Ishii S; Ibaragi S; Hirai K; Yamashiro K; Yamamoto T; Suga S; Takashiba S
Int Immunopharmacol; 2020 Jun; 83():106429. PubMed ID: 32222639
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
[TBL] [Abstract][Full Text] [Related]
16. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
17. Parthenolide inhibits osteoclast differentiation and bone resorbing activity by down-regulation of NFATc1 induction and c-Fos stability, during RANKL-mediated osteoclastogenesis.
Kim JY; Cheon YH; Yoon KH; Lee MS; Oh J
BMB Rep; 2014 Aug; 47(8):451-6. PubMed ID: 24314143
[TBL] [Abstract][Full Text] [Related]
18. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
[TBL] [Abstract][Full Text] [Related]
19. The Coumarin Derivative 5'-Hydroxy Auraptene Suppresses Osteoclast Differentiation via Inhibiting MAPK and c-Fos/NFATc1 Pathways.
Abdallah BM; Ali EM; Elsawy H; Badr GM; Abdel-Moneim AM; Alzahrani AM
Biomed Res Int; 2019; 2019():9395146. PubMed ID: 31976330
[TBL] [Abstract][Full Text] [Related]
20. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
